WO2002024929A3 - A SOLUBLE BETA 2 MICROGLOBULIN (β2M)/HFE MONOCHAIN FOR BIOTECHNOLOGICAL AND THERAPEUTIC APPLICATIONS - Google Patents

A SOLUBLE BETA 2 MICROGLOBULIN (β2M)/HFE MONOCHAIN FOR BIOTECHNOLOGICAL AND THERAPEUTIC APPLICATIONS Download PDF

Info

Publication number
WO2002024929A3
WO2002024929A3 PCT/US2001/029873 US0129873W WO0224929A3 WO 2002024929 A3 WO2002024929 A3 WO 2002024929A3 US 0129873 W US0129873 W US 0129873W WO 0224929 A3 WO0224929 A3 WO 0224929A3
Authority
WO
WIPO (PCT)
Prior art keywords
hfe
monochain
microglobulin
biotechnological
therapeutic applications
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2001/029873
Other languages
French (fr)
Other versions
WO2002024929A2 (en
Inventor
Rachel Ehrlich
Rinat Rotem-Yehudar
Nihay Laham
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ramot at Tel Aviv University Ltd
Original Assignee
Ramot at Tel Aviv University Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ramot at Tel Aviv University Ltd filed Critical Ramot at Tel Aviv University Ltd
Priority to AU2001296303A priority Critical patent/AU2001296303A1/en
Publication of WO2002024929A2 publication Critical patent/WO2002024929A2/en
Anticipated expiration legal-status Critical
Publication of WO2002024929A3 publication Critical patent/WO2002024929A3/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A soluble beta2m/HFE monochain which is a polypeptide comprising human beta2m, or an analog or active fragment thereof, linked to the alphal-alpha3 domains of human HFE, or an analog or active fragment thereof, by means of a flexible linker peptide, or a functional derivative or salt of said polypeptide. This invention also relates to therapeutic interventions for iron overload disorders and chronic infections.
PCT/US2001/029873 2000-09-22 2001-09-24 A SOLUBLE BETA 2 MICROGLOBULIN (β2M)/HFE MONOCHAIN FOR BIOTECHNOLOGICAL AND THERAPEUTIC APPLICATIONS Ceased WO2002024929A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001296303A AU2001296303A1 (en) 2000-09-22 2001-09-24 A soluble beta 2 microglobulin (beta2m)/hfe monochain for biotechnological and therapeutic applications

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23484300P 2000-09-22 2000-09-22
US60/234,843 2000-09-22

Publications (2)

Publication Number Publication Date
WO2002024929A2 WO2002024929A2 (en) 2002-03-28
WO2002024929A3 true WO2002024929A3 (en) 2003-05-08

Family

ID=22883039

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/029873 Ceased WO2002024929A2 (en) 2000-09-22 2001-09-24 A SOLUBLE BETA 2 MICROGLOBULIN (β2M)/HFE MONOCHAIN FOR BIOTECHNOLOGICAL AND THERAPEUTIC APPLICATIONS

Country Status (2)

Country Link
AU (1) AU2001296303A1 (en)
WO (1) WO2002024929A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007508806A (en) * 2003-08-04 2007-04-12 アプライド リサーチ システムズ エーアールエス ホールディング ナームロゼ フェンノートシャップ Novel therapeutic fusion protein
EP2374470A1 (en) * 2010-04-08 2011-10-12 Beta Innov Therapeutic use of the Beta2m protein
CN116515000A (en) * 2023-06-30 2023-08-01 迦进生物医药(上海)有限公司 HFE fusion proteins and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5739281A (en) * 1993-02-04 1998-04-14 Denzyme Aps Interative method of at least three cycles for the refolding of proteins
US6011146A (en) * 1991-11-15 2000-01-04 Institut Pasteur Altered major histocompatibility complex (MHC) determinant and methods of using the determinant
WO2000037482A2 (en) * 1998-12-18 2000-06-29 Progenitor, Inc. Peptides and peptide analogues designed from hfe protein and their uses in the treatment of iron overload diseases

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6011146A (en) * 1991-11-15 2000-01-04 Institut Pasteur Altered major histocompatibility complex (MHC) determinant and methods of using the determinant
US5739281A (en) * 1993-02-04 1998-04-14 Denzyme Aps Interative method of at least three cycles for the refolding of proteins
WO2000037482A2 (en) * 1998-12-18 2000-06-29 Progenitor, Inc. Peptides and peptide analogues designed from hfe protein and their uses in the treatment of iron overload diseases

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
FEDER ET AL: "A NOVEL MHC CLASS I-LIKE GENE IS MUTATED IN PATIENTS WITH HEREDITARY HAEMOCHROMATOSIS", NATURE GENETICS, NEW YORK, NY, US, vol. 13, August 1996 (1996-08-01), pages 399 - 408, XP002113585, ISSN: 1061-4036 *
GUSSOW D ET AL: "THE HUMAN BETA-2 MICROGLOBULIN GENE PRIMARY STRUCTURE AND DEFINITION OF THE TRANSCRIPTIONAL UNIT", JOURNAL OF IMMUNOLOGY, vol. 139, no. 9, 1987, pages 3132 - 3138, XP002214372, ISSN: 0022-1767 *
IKUTA K ET AL: "Overexpression of hemochromatosis protein, HFE, alters transferrin recycling process in human hepatoma cells", BIOCHIMICA ET BIOPHYSICA ACTA. MOLECULAR CELL RESEARCH, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 1496, no. 2-3, 17 April 2000 (2000-04-17), pages 221 - 231, XP004278134, ISSN: 0167-4889 *

Also Published As

Publication number Publication date
WO2002024929A2 (en) 2002-03-28
AU2001296303A1 (en) 2002-04-02

Similar Documents

Publication Publication Date Title
CH1143977H1 (en) 2-Oxy-benzoxazine-4-ones for the treatment of obesity
TNSN96066A1 (en) RECOMBINANT OBESES (OB) PROTEINS
EP1284728A4 (en) DRUGS FOR THE TREATMENT OF OBESITY
NO20000396L (en) Catalytic monoclonal antibodies with protease activity for selective lysis of the protein component of plaques and aggregates related to pathological conditions
WO2000020612A3 (en) Therapeutically active proteins in plants
ATE348113T1 (en) RECOMBINANT ANTI-CD4 ANTIBODY FOR HUMAN TREATMENT
WO2004078777A3 (en) Dipeptidyl-peptidase protected proteins
AU2002308289A1 (en) Highly flexible transdermal therapeutic system having nicotine as active substance
IL157692A0 (en) Highly flexible transdermal therapeutic system having nicotine as active substance
WO2005061532A8 (en) Pathogenic infection detection compositions and methods
WO2001064877A3 (en) Human schizophrenia gene
WO2001080873A3 (en) Thrombopoietin receptor modulating peptide
ITVI970167A0 (en) COVERING STRUCTURE FOR THE DRIVER'S POSITION OF OPERATING MACHINES.
WO2002100152A3 (en) Solution-phase combinatiorial library synthesis and pharmaceutically active compounds produced thereby
WO2002024929A3 (en) A SOLUBLE BETA 2 MICROGLOBULIN (β2M)/HFE MONOCHAIN FOR BIOTECHNOLOGICAL AND THERAPEUTIC APPLICATIONS
WO2002100895A3 (en) Antimicrobially active peptide
EP1501861A4 (en) TARGETING PROTEINS FOR THE DELIVERY OF THERAPEUTIC OR DIAGNOSTIC REAGENTS
WO2003062276A3 (en) Multimers of receptor-binding ligands
AU7216498A (en) Inhibitors of the urokinase receptor
WO2001064876A3 (en) Human schizophrenia gene
WO2001007479A3 (en) Fragments of cellular prion protein and methods useful in the diagnosis and treatment of prion diseases
TR200102655T2 (en) Chimeric gene encoding antigen markers of four L. infantum proteins.
WO2005086825A3 (en) Methods and compositions for treatment of diseases associated with aberrant microsatellite expansion
WO2001051511A3 (en) Recombinant production of human histone-1 subtypes and use thereof for therapeutic purposes
WO2004100882A3 (en) Inhibition of drug binding to serum albumin

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP